

SELLTP: Rs 230 | **▼** 11%

WIPRO

IT Services

18 July 2019

Another disappointing quarter

Wipro (WPRO) reported another tepid quarter as a wind-down of large projects in the retail & CPG verticals and delayed ramp-up of some contracts led to a dollar revenue decline of 1.8% QoQ. Adj. IT services EBIT margin at 17.9% was below estimates. Q2 revenue growth guidance of 0-2% QoQ was uninspiring. We tweak estimates but retain our TP at Rs 230 upon rollover to Jun'20. A muted BFSI outlook, regulatory uncertainty in healthcare, and restructuring of India & Middle East operations continue to hamper recovery prospects.

Ruchi Burde research@bobcaps.in

Poor operating performance: WPRO reported a 1.8% QoQ drop in dollar revenues for Q1FY20 vs. our/street estimates of a 0.9%/0.2% QoQ decline. Reported IT services EBIT margins at 18.4% (-80bps QoQ) were in line, albeit aided by Rs 669mn of exceptional gains on divestment of businesses. Adjusted for this, margins at 17.9% came in lower than estimates.

Uninspiring Sep'19 quarter guidance: Q2FY20 revenue growth guidance of 0-2% QoQ was subdued and below our estimate of 1-3% sequential growth. We highlight that the Sep'19 quarter will include inorganic revenues from consolidation of International TechneGroup (which had annual revenues of US\$ 23.2mn in FY18). The midpoint of the guided range implies moderation of WPRO's annual growth trajectory to low single-digits for FY20.

Retain SELL: We cut FY20/FY21 EPS estimates by 1.6%/2.1% as we accommodate the muted Jun'19 quarter performance. In our view, a growth recovery will continue to elude WPRO, inviting downside risks to consensus earnings estimates. We model for a 6.4% earnings CAGR over FY19-FY21 and retain SELL with an unchanged Jun'20 TP of Rs 230, valuing the stock at 13.5x one-year forward P/E.

Ticker/Price	WPRO IN/Rs 260
Market cap	US\$ 17.0bn
Shares o/s	4,512mn
3M ADV	US\$ 27.3mn
52wk high/low	Rs 302/Rs 198
Promoter/FPI/DII	74%/9%/17%

Source: NSE

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY17A	FY18A	FY19A	FY20E	FY21E
Adj. net profit (Rs mn)	82,723	80,046	90,074	89,218	96,547
Adj. EPS (Rs)	12.8	13.3	14.9	15.6	16.9
Adj. EPS growth (%)	(5.8)	4.0	12.3	4.6	8.2
Adj. ROAE (%)	16.7	15.9	17.1	16.0	16.4
Adj. P/E (x)	20.3	19.5	17.4	16.6	15.3
EV/EBITDA (x)	10.6	12.0	10.0	9.3	8.7

Source: Company, BOBCAPS Research





FIG 1 – JUN'19 QUARTER PERFORMANCE

(Rs mn)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Y ₀ Y (%)	Q ₀ Q (%)
US\$ revenues (IT Services excluding ISRE)*	1,989	2,010	2,047	2,076	2,039	2.5	(1.8)
Total revenue	1,40,548	1,46,627	1,51,506	1,50,379	1,48,019	5.3	(1.6)
Operating expenditure	1,19,771	1,21,139	1,22,838	1,23,125	1,23,345	3.0	0.2
Cost of revenues	1,00,350	1,01,770	1,03,971	1,05,462	1,04,273	3.9	(1.1)
as % of sales	71.4	69.4	68.6	70.1	70.4	-	-
SG&A expenses	19,421	19,369	18,867	17,663	19,072	(1.8)	8.0
as % of sales	13.8	13.2	12.5	11.7	12.9	-	-
EBIT	20,777	25,488	28,668	27,254	24,674	18.8	(9.5)
Other Income	6,024	(1,285)	3,742	4,747	6,045	0.3	27.3
РВТ	26,801	24,203	32,410	32,001	30,719	14.6	(4.0)
Total Tax	5,865	5,347	6,966	7,064	6,699	14.2	(5.2)
Adjusted PAT	20,936	18,856	25,444	24,937	24,020	14.7	(3.7)
(Profit)/loss from JV's/Ass/MI	270	33	(341)	(104)	(147)	-	-
APAT after MI	21,206	18,889	25,103	24,833	23,873	12.6	(3.9)
Extra ordinary items	0	0	0	0	0	-	-
Reported PAT	21,206	18,889	25,103	24,833	23,873	12.6	(3.9)
Reported EPS	3.5	3.1	4.2	4.1	4.0	12.3	(3.9)
Margins (%)						(bps)	(bps)
EBIT margin-IT Services (excluding ISRE)	17.6	18.4	19.8	19.2	17.9	34	(126)
EBIT	14.8	17.4	18.9	18.1	16.7	189	(145)
EBT	19.1	16.5	21.4	21.3	20.8	168	(53)
PAT	15.1	12.9	16.6	16.5	16.1	104	(39)
Effective Tax rate	21.9	22.1	21.5	22.1	21.8	(8)	(27)

Source: BOBCAPS Research | *Indian State Run Enterprises.

Earnings call highlights

- Management pointed to a "stable" demand environment but cautioned about slower decision-making in pockets of BFSI, namely capital markets and European banks – commentary similar to that of TCS and Infosys.
- Management is hopeful of regaining growth momentum through the rest of FY20 aided by a strong deal pipeline.
- WPRO awaits clarity on the buyback tax in the final finance bill and remains committed to completing its plan of capital return to shareholders.
- The company has achieved 65% localisation in North America.



Valuation methodology

Despite several strategic interventions, WPRO has underperformed its tier-I IT service peers in terms of revenues and earnings over the past seven years. Regulatory uncertainty for the healthcare business, restructuring of India and Middle East operations, and a muted outlook for the BFSI and manufacturing verticals cloud recovery prospects. While we acknowledge that the company's strategic moves are steps in the right direction, we believe patchy, inconsistent execution will remain a drag on growth.

We cut FY20/FY21 EPS estimates by 1.6%/2.1% as we accommodate the muted Jun'19 quarter performance. Upon rolling valuations forward, our Jun'20 target price remains unchanged at Rs 230, set at 13.5x one-year forward P/E. Maintain SELL.

FIG 2 - REVISED ESTIMATES

(D.)	FY20E			FY21E		
(Rs mn)	Old	New	Change (%)	Old	New	Change (%)
IT Services revenues (excluding ISRE, in US\$ mn)	8,488	8,299	(2.2)	9,080	8,857	(2.5)
IT Services revenues (excluding ISRE, in US\$ mn), YoY growth (%)	4.5	2.2	-	7.0	6.7	-
Company-wide revenues	6,12,162	5,91,012	(3.5)	6,55,012	6,35,753	(2.9)
EBIT	1,05,890	1,02,726	(3.0)	1,14,089	1,11,635	(2.2)
EBIT margins (%)	17.3	17.4	-	17.4	17.6	-
Net profits	90,569	89,218	(1.5)	98,420	96,547	(1.9)
EPS (Rs)	15.9	15.6	(1.6)	17.3	16.9	(2.1)

Source: BOBCAPS Research

FIG 3 - RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

Upside risks to our estimates include:

- a sharper recovery in demand than expected,
- stronger-than-estimated large deal wins, and
- sharp, favourable currency movements.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY17A	FY18A	FY19A	FY20E	FY21E
Total revenue	5,54,179	5,46,359	5,89,060	5,91,012	6,35,753
EBITDA	1,12,904	1,05,418	1,27,072	1,19,485	1,35,789
EBIT	89,797	84,294	1,02,187	1,02,726	1,11,635
Net interest income/(expenses)	13,521	18,169	15,548	14,148	13,992
Other income/(expenses)	4,867	0	0	0	0
Exceptional items	0	0	0	0	0
EBT	1,08,185	1,02,463	1,15,458	1,16,175	1,25,626
Income taxes	25,214	22,390	25,242	26,661	28,879
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	248	27	142	297	200
Reported net profit	82,723	80,046	90,074	89,218	96,547
Adjustments	0	0	0	0	0
Adjusted net profit	82,723	80,046	90,074	89,218	96,547

Balance Sheet

Y/E 31 Mar (Rs mn)	FY17A	FY18A	FY19A	FY20E	FY21E
Accounts payables	0	0	0	0	0
Other current liabilities	1,20,521	1,33,177	1,58,894	1,31,156	1,41,085
Provisions	1,274	799	640	1,457	1,568
Debt funds	1,42,412	1,38,259	99,467	99,467	99,467
Other liabilities	6,614	3,059	3,417	3,417	3,417
Equity capital	4,861	9,048	12,068	12,068	12,068
Reserves & surplus	5,17,834	4,76,298	5,58,685	5,32,462	6,17,590
Shareholders' fund	5,22,695	4,85,346	5,70,753	5,44,530	6,29,658
Total liabilities and equities	7,93,516	7,60,640	8,33,171	7,80,027	8,75,194
Cash and cash eq.	52,710	44,925	1,58,529	89,969	1,65,965
Accounts receivables	98,844	1,00,990	1,00,489	1,06,868	1,14,958
Inventories	3,915	3,370	3,951	4,858	5,225
Other current assets	1,12,296	1,45,107	1,29,457	1,30,346	1,40,214
Investments	2,99,133	2,59,200	2,33,798	2,33,798	2,33,798
Net fixed assets	69,794	64,443	70,601	77,842	78,688
CWIP	8,951	15,166	0	0	0
Intangible assets	1,41,718	1,35,697	1,30,742	1,30,742	1,30,742
Deferred tax assets, net	15,106	6,908	5,604	5,604	5,604
Other assets	0	0	0	0	0
Total assets	7,93,516	7,60,640	8,33,171	7,80,027	8,75,194

Source: Company, BOBCAPS Research



Cash Flows

Y/E 31 Mar (Rs mn)	FY17A	FY18A	FY19A	FY20E	FY21E
Net income + Depreciation	82,803	73,043	1,15,101	1,06,273	1,20,902
Interest expenses	0	0	(15,548)	(14,148)	(13,992)
Non-cash adjustments	0	0	0	0	0
Changes in working capital	4,511	(877)	41,128	(35,096)	(8,286)
Other operating cash flows	5,459	12,067	14,424	0	0
Cash flow from operations	92,773	84,233	1,55,105	57,030	98,624
Capital expenditures	(19,646)	(20,699)	(46,209)	(24,000)	(25,000)
Change in investments	(83,684)	47,973	0	0	0
Other investing cash flows	(12,373)	8,679	15,548	14,148	13,992
Cash flow from investing	(1,15,703)	35,953	(30,661)	(9,852)	(11,008)
Equities issued/Others	0	24	0	(1,05,000)	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	(14,018)	(1,24,582)	0	0	0
Dividends paid	(8,734)	(5,420)	(10,840)	(10,737)	(11,619)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(22,752)	(1,29,978)	(10,840)	(1,15,737)	(11,619)
Changes in cash and cash eq.	(45,682)	(9,792)	1,13,604	(68,560)	75,996
Closing cash and cash eq.	52,710	44,925	1,58,529	89,969	1,65,965

Per Share

Y/E 31 Mar (Rs)	FY17A	FY18A	FY19A	FY20E	FY21E
Reported EPS	12.8	13.3	14.9	15.6	16.9
Adjusted EPS	12.8	13.3	14.9	15.6	16.9
Dividend per share	2.0	1.0	1.5	1.6	1.7
Book value per share	80.8	80.7	94.7	95.4	110.4

Valuations Ratios

Y/E 31 Mar (x)	FY17A	FY18A	FY19A	FY20E	FY21E
EV/Sales	2.2	2.3	2.1	1.9	1.9
EV/EBITDA	10.6	12.0	10.0	9.3	8.7
Adjusted P/E	20.3	19.5	17.4	16.6	15.3
P/BV	3.2	3.2	2.7	2.7	2.4

DuPont Analysis

Y/E 31 Mar (%)	FY17A	FY18A	FY19A	FY20E	FY21E
Tax burden (Net profit/PBT)	76.5	78.1	78.0	76.8	76.9
Interest burden (PBT/EBIT)	120.5	121.6	113.0	113.1	112.5
EBIT margin (EBIT/Revenue)	16.2	15.4	17.3	17.4	17.6
Asset turnover (Revenue/Avg TA)	73.0	70.3	73.9	73.3	76.8
Leverage (Avg TA/Avg Equity)	1.5	1.5	1.5	1.4	1.4
Adjusted ROAE	16.7	15.9	17.1	16.0	16.4

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis

Y/E 31 Mar	FY17A	FY18A	FY19A	FY20E	FY21E
YoY growth (%)					
Revenue	7.3	(1.4)	7.8	0.3	7.6
EBITDA	1.1	(6.6)	20.5	(6.0)	13.6
Adjusted EPS	(5.8)	4.0	12.3	4.6	8.2
Profitability & Return ratios (%)					
EBITDA margin	20.4	19.3	21.6	20.2	21.4
EBIT margin	16.2	15.4	17.3	17.4	17.6
Adjusted profit margin	14.9	14.7	15.3	15.1	15.2
Adjusted ROAE	16.7	15.9	17.1	16.0	16.4
ROCE	16.0	14.0	18.6	19.1	19.8
Working capital days (days)					
Receivables	66	67	62	64	64
Inventory	4	3	3	3	4
Payables	96	100	109	108	95
Ratios (x)					
Gross asset turnover	8.2	8.1	8.7	8.0	8.1
Current ratio	2.2	2.2	2.5	2.5	3.0
Net interest coverage ratio	6.6	4.6	6.6	7.3	8.0
Adjusted debt/equity	0.2	0.2	(0.1)	0.0	(0.1)

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: WIPRO (WPRO IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 30 June 2019, out of 76 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 15 are rated ADD, 10 are rated REDUCE and 8 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance, wealth management and portfolio management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

WIPRO



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

 ${\sf BOBCAPS} \ or \ its \ research \ analyst(s) \ is \ not \ engaged \ in \ any \ market \ making \ activities \ for \ the \ subject \ company.$

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.